CNS Pharmaceuticals Company Presentation

CNS pharmaceuticals 4 Investment Highlights. • Focusing on unmet need as glioblastoma multiforme (GBM) is an aggressive and incurable form of brain cancer - Orphan drug designation opportunity - Upside in additional cancer types • Lead drug candidate developed Dr. Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center - First anthracycline shown to cross the blood-brain barrier in adults - Positive Phase 1 results - Pivotal Phase 2 clinical trial expected to commence in Q1 2021 • Clinical development partnership enhances ability to advance drug in the clinic - R&D commitments for commercial rights in Eastern Europe and Central Asia - Received $6 million in grants to perform to clinical studies - First-ever Phase 1 pediatric study to be performed • Pipeline includes novel class of potential DNA binding therapeutics, shown to be 500x more potent than classic DNA binders in animal testing • Appointed Dr. Patrick Wen to the Scientific Advisory Board. Dr. Wen is the Director of the Center for Neuro-Oncology at Dana Farber Cancer Institute, a Professor of Neurology at Harvard Medical School and is a member of the Board of Directors and immediate past President of the Society for Neuro-Oncology. • Collaborating with leading expert investigators